Direct vasoprotection by aspirin: a significant bonus to antiplatelet activity?
Georg
G
Kojda
D001241:Aspirin / Q000627:therapeutic use*; D003327:Coronary Disease / Q000378:metabolism / Q000517:prevention & control*; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use*; D003864:Depression, Chemical; D004730:Endothelium, Vascular / Q000378:metabolism*; D006801:Humans; D020781:Matrix Metalloproteinase 1 / Q000378:metabolism; D018384:Oxidative Stress / Q000187:drug effects; D011973:Receptors, LDL / Q000378:metabolism; D051131:Receptors, Oxidized LDL; D051127:Scavenger Receptors, Class E
D016861:Cyclooxygenase Inhibitors; C495137:OLR1 protein, human; D011973:Receptors, LDL; D051131:Receptors, Oxidized LDL; D051127:Scavenger Receptors, Class E; D020781:Matrix Metalloproteinase 1; D001241:Aspirin